Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at B. Riley from $7.00 to $9.00. They now have a "buy" rating on the stock.
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at Guggenheim.
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer